Eficácia e tolerância do nitrofurfurilidene (1) na fase crônica da Moléstia de Chagas

Silva, Newton Neves da; Kuhn, Gisebel; Santos, João Francisco Cardoso dos; Eye, Günther Von; Chaher, João Aloisio Braga

doi:10.1590/s0037-86821974000600003

Cited by 7 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For acute cases and recent infections an average index of parasitological cure around 60% is estimated. In relation to chronic infection cases, results have been poor, for the Brazilian experience, while in the South Cone, they were much better, possibly due to the type of parasite strain (Silva et al 1974, Cerisola et al 1977.…”

Section: Effect Of the Treatment On The Evolution Of Chagas Diseasementioning

confidence: 99%

“…Since 1969 several therapeutic experiences have been performed in acute and chronic cases of Chagas disease using Nif (Bocca-Tourres 1969, Rubio & Donoso 1969, Schenone et al 1969, 1972, Rassi & Ferreira 1971, Cerisola et al 1972, Silva et al 1974, Prata et al 1975, Cançado et al 1975, 1976, Cançado & Brener 1979, Bz (Schenone et al 1975, Ferreira 1976, Coura et al 1978, Viotti et al 1994, Andrade et al 1996, Sosa Estani et al 1998) and also comparing the efficacy and tolerance of both drugs in different groups of patients, therapeutic schemes and periods of follow-up and cure evaluation criteria (Schenone et al 1981, Ferreira 1990, Lazzari & Freilig 1998.…”

Section: Effect Of the Treatment On The Evolution Of Chagas Diseasementioning

confidence: 99%

See 1 more Smart Citation

A Critical Review on Chagas Disease Chemotherapy

Coura¹,

Castro

2002

Mem. Inst. Oswaldo Cruz

826

444

View full text Add to dashboard Cite

Section: Effect Of the Treatment On The Evolution Of Chagas Diseasementioning

confidence: 99%

Section: Effect Of the Treatment On The Evolution Of Chagas Diseasementioning

confidence: 99%

A Critical Review on Chagas Disease Chemotherapy

Coura¹,

Castro

2002

Mem. Inst. Oswaldo Cruz

826

444

View full text Add to dashboard Cite

“…36 The mean estimated parasitological cure rate is around 60% for acute cases and recent infections. Results are considered poor for chronic infections, in the Brazilian experience; in the Southern Cone, results were considered superior, probably owing to a different parasite strain (Silva et al 1974;Cerisola et al, 1977). 37,38 The clinical progression of Chagas disease after specific treatment is controversial and study results are inconclusive due to differences in cases, assessment methods, follow-up periods, and data interpretation.…”

Section: Specific Treatment Of Chagas Diseasementioning

confidence: 99%

Revisiting the History of Chagas Disease: "Live to tell"

Cunha¹,

Cunha²

2021

International Journal of Cardiovascular Sciences

View full text Add to dashboard Cite

In 1907, Carlos Chagas was designated to fight paludism in the Rio das Velhas region along the Central do Brasil railroad. During his field research, Chagas discovered a hematophagous insect (Panstrongylus megitus) carrying a new trypanosomatide, which he named Trypanosoma cruzi. On April 14th, 1909, he found the same parasite in the blood of a febrile child, submitting the announcement of his discoveries to the Brasil Médico scientific journal.Here, we discuss the early stages in the establishment of a new human morbid entity during the first decades after its discovery with a definite influence from its discoverer, Carlos Chagas, as well the first collaborators. Moreover, we cover the importance of the Center for the Study and Prophylaxis of Chagas Disease in Bambuí (MG), unraveling the most advanced developments in research within the disease's habitat and the widening perspectives for modern research that have emerged after the 1960s and continue to improve to this day.In this revisitation to the history of Chagas disease, we begin at Manguinhos (RJ ), making our way to Lassance (MG), where the discovery took place. Then, we travel back to Rio de Janeiro in the beginning of the twentieth century and Brazilian republic until the current day, revealing milestone publications that settled Chagas disease both as a source of pride for Brazilian medicine and as a challenge with important aspects that remain to be clarified. Any similarities to our country's politics and economy in the twentieth century are not mere coincidences. Carlos Chagas's research in the semi-arid region of Minas Gerais began in 1907 with the campaign against paludism in the Rio das Velhas river valley, aiming to save the lives of workers who worked in the expansion of the Central do Brasil railroad. The finding of a hematophagous insect (Panstrongylus megitus), strictly adapted to the domestic environment, with nocturnal habits and commonly known as the "barber bug" or "kissing bug" surprised Chagas, who intensified his research and found, in this insect, a new trypanosomatide named Trypanosoma cruzi. The further identification of T. cruzi in the blood of domestic animals and in the human blood directed Carlos Chagas to systematize a new human morbid entity.The choice of Carlos Chagas for the noble mission of battling malaria was due in great part to his strong scientific background on the theme with the completion, in Manguinhos, of his doctoral thesis named "Hematological studies of paludism," presented in 1903. This knowledge prompted him to systematize, in 1905, the household theory of infection by paludism. In 1907, Chagas participated in the group of scientists conducting the most brilliant research at the time, being designated to the anti-paludism campaign in Minas Gerais where, in Lassance, his path became the track for one of the most fascinating discoveries in the history of Medicine. Raquel Lewinsohn 1 and Berning 2 consider that Carlos Chagas, through his example, his life, and the aspects of his discovery, is unique in the hist...

show abstract

“…15 Some reports did show differences for another drug, nifurtimox, which has had good performance in Argentina, Chile, and south of Brazil (bordering Argentina) but poor results in central Brazil. 16 Another reason for this discrepancy may be the low number of xenodiagnosis examinations, a mean of two or three xenodiagnoses after treatment, in the study reported by Gallerano and others 5 and seven in the study of Apt and others. 12 It is well known that the sensitivity of xenodiagnosis is low, and the only way to augment it is by increasing the number of examinations.…”

mentioning

confidence: 97%

Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease

Luquetti¹,

Rassi²,

Rassi³

et al. 2007

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Thirty-five individuals from endemic areas of Central Brazil (age range, 18-64 years; 19 women) in the chronic phase of Chagas disease, with positive serology and presence of circulating parasites detected by one or more recent positive xenodiagnosis, were selected for this study. Allopurinol (900 mg/d) or placebo was administered in a double-blind clinical trial for 60 days. After codes were broken, 23 had been allocated to the intervention group and 12 to the placebo group. Side effects were observed in 11 patients in the intervention group and in 1 in the placebo group. Seventeen patients in the intervention group and 10 in the placebo group completed the trial. Follow-up was performed by monthly xenodiagnosis and serologic tests every 3 months during the first year and at the end of the trial. Xenodiagnosis remained positive in all 17 of the treated group and in all 10 of the placebo group. Serologic tests were persistently positive in both groups after treatment. We concluded that, at the doses used, allopurinol was not effective to clear, in our region, Trypanosoma cruzi from peripheral blood of infected individuals.

show abstract

Eficácia e tolerância do nitrofurfurilidene (1) na fase crônica da Moléstia de Chagas

Cited by 7 publications

References 2 publications

A Critical Review on Chagas Disease Chemotherapy

A Critical Review on Chagas Disease Chemotherapy

Revisiting the History of Chagas Disease: "Live to tell"

Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease

Contact Info

Product

Resources

About